% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{PletschBorba:148300,
      author       = {L. Pletsch-Borba$^*$ and C. Watzinger$^*$ and R. Turzanski
                      Fortner$^*$ and V. Katzke$^*$ and L. Schwingshackl and S.
                      Sowah$^*$ and A. Hüsing$^*$ and T. Johnson$^*$ and M.-L.
                      Groß and S. González Maldonado$^*$ and M. Hoffmeister$^*$
                      and P. Bugert and R. Kaaks$^*$ and M. Grafetstätter$^*$ and
                      T. Kühn$^*$},
      title        = {{B}iomarkers of {V}ascular {I}njury and {T}ype 2
                      {D}iabetes: {A} {P}rospective {S}tudy, {S}ystematic {R}eview
                      and {M}eta-{A}nalysis.},
      journal      = {Journal of Clinical Medicine},
      volume       = {8},
      number       = {12},
      issn         = {2077-0383},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2019-02864},
      pages        = {2075},
      year         = {2019},
      abstract     = {Data on biomarkers of vascular injury and type 2 diabetes
                      (T2D) risk from prospective studies are lacking. We
                      evaluated seven biomarkers of vascular injury in relation to
                      T2D. Additionally, a meta-analysis was performed. From the
                      EPIC-Heidelberg cohort, 2224 participants were followed-up
                      from baseline for 16 (median) years. E-Selectin, P-Selectin,
                      intercellular adhesion molecule 3 (ICAM3), thrombomodulin,
                      thrombopoietin, glycoprotein IIb/IIIa and fibrinogen levels
                      were measured in baseline blood samples. The systematic
                      review and meta-analysis included prospective studies
                      identified through MEDLINE and Web of Science that
                      investigated the association between mentioned biomarkers
                      and T2D. The study population included $55\%$ women, median
                      age was 50 years, and 163 developed T2D. ICAM3 was
                      associated with lower T2D risk (fully adjusted HRhighest vs.
                      lowest tertile 0.62 $(95\%$ CI: 0.43, 0.91)), but no other
                      studies on ICAM3 were identified. Overall, fifteen studies
                      were included in the systematic review and meta-analysis
                      (6,171 cases). E-Selectin was associated with higher T2D
                      risk HRper SD: 1.34 $(95\%$ CI: 1.16, 1.54; I2 = $63\%,$ n =
                      9 studies), while thrombomodulin was associated with lower
                      risk HRper SD: 0.82 $(95\%$ CI: 0.71, 0.95; I2 = $0\%,$ n =
                      2 studies). In the EPIC-Heidelberg, ICAM3 was associated
                      with lower T2D risk. The meta-analysis showed a consistent
                      positive association between E-Selectin and T2D. It was also
                      suggestive of an inverse association between thrombomodulin
                      and T2D, although further studies are needed to corroborate
                      this finding.},
      subtyp        = {Review Article},
      cin          = {C020 / C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)C070-20160331},
      pnm          = {323 - Metabolic Dysfunction as Risk Factor (POF3-323)},
      pid          = {G:(DE-HGF)POF3-323},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31783601},
      doi          = {10.3390/jcm8122075},
      url          = {https://inrepo02.dkfz.de/record/148300},
}